Yangtze River Life Science and Technology lost 190 million last year

SighingCashier · 2026-03-17T13:13:34+00:00

Yangtze River Life Sciences Technology reported a loss of 187 million yuan as of last year, with revenue of 5.41 billion yuan, a decrease of 2.04%. The expanded loss was attributed to increased R&D expenses and non-cash items. Chairman Li Ze-jue expects the operating environment uncertainty to persist and plans a reorganization to accelerate R&D progress, with the outlook that future commercial operations will continue to support the company's development.

SighingCashier

2026-03-17 13:13:34

Abstract generation in progress

Yangtze River Life Sciences (00775) announced that for the year ending December 2022, the loss was HKD 187 million, with a loss of HKD 1.94 cents per share, and no final dividend will be paid; the loss for the same period in 2024 was HKD 127 million.

During the period, revenue was HKD 5.41 billion, a decrease of 2.04% year-on-year.

The company stated that the increased loss last year reflected higher R&D expenses of HKD 66.5 million, as well as several non-cash special items and one-time charges, including a significant decline in the valuation of the vineyard asset portfolio, several provisions, and transaction gains related to the R&D subsidiary Polynoma and Nasdaq-listed company RNAZ.

Excluding a one-time net gain from the sale of vineyards in 2024 and special items in 2025, the net profit from business operations after tax in 2025 was HKD 130 million, an increase of HKD 42.6 million year-on-year.

Chairman Li Zeju stated in the earnings report that, given the ongoing changes in geopolitical situations and the global economic environment, the uncertainty in the operating environment is expected to continue. Yangtze River Life Sciences has introduced more expertise and ample funds through restructuring to accelerate R&D progress. With continued support for its business operations, the company will further expand the prospects of its R&D achievements by establishing clear strategic priorities and high-efficiency development.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.